→ The COPD drug market is expected to grow dramatically over the next decade, hitting $14.1 billion by 2025, according to GlobalData. It was $9.9 billion in 2015. The growth will be fueled by increased diagnoses as well as new bronchodilator drug classes and anti-eosinophilic biologics.
→ Valeant is selling iNova for $930 million. The company is selling off assets in an attempt to reduce large piles of debt acquired under previous CEO Mike Pearson as he went on a deal-making spree. Pearson was replaced by Joseph Papa last year.
→ CytRx announced it plans to submit a rolling NDA under section 505(b)(2) New Drug Application (NDA) for aldoxorubicin, which has received orphan drug designation, in soft tissue sarcomas (STS). The drug flopped in 2016.
→ Exact Sciences Corporation $EXAS is selling 7m shares of common stock at a public offering price of $35 per share. It’s expected to close June 12.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.
Free Subscription
LATEST
FEATURED
SIMILAR
Subscriber Comments
There are no comments so far. Add your own?